The proportion of memory and CD20+CD8+ T cells, specific for myelin antigens, was significantly reduced following anti-CD20 treatment, indicating that the depletion of CD20+ T cells has therapeutic potential in MS (190). The gene discussed is CD8A; the disease is myeloid sarcoma.